Kalaris Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Kalaris Therapeutics reported Q2 2026 net loss of $11.5M (vs. $11.4M in Q2 2025); cash, equivalents, and marketable securities decreased from $118.0M (Dec 31, 2025) to $93.5M (June 30, 2026), a burn of $24.5M in 6 months. The company states this cash will fund operations through Q4 2027 and key clinical milestones. TH103 Phase 1b/2 dosing continues in nAMD; preliminary data expected H1 2027; Phase 3 initiation targeted by year-end 2027. Leadership additions: Liisa Bayko as CFO and Laurie Keating to Board.
Why this rating
Clinical-stage biotech; moderate burn (~$24.5M/6mo) against $12.6M market cap signals execution risk and dilution. Program on track but pre-revenue; cash runway adequate per guidance. News is routine clinical/financial update.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.